JEONJINBIO CO., LTD. Q3 operating loss of KRW 0.3 billion, swinging to a loss; revenue KRW 3.4 billion
AI summary · Not investment advice
Jeonjin Biopharm sold KRW 3.4 billion worth in Q3 but lost KRW 0.3 billion from its main business, turning from profit to loss versus a year earlier.
Operating profit · 3 months
KRW -328.3 million
Key facts
- Revenue (3 months)
- KRW 3.4 billion
- Net income (3 months)
- KRW -321.9 million
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 4.5 billion
- Revenue (year to date)
- KRW 9.2 billion
- Operating profit (prior-year 3 months)
- KRW 325.5 million
- Operating profit (year to date)
- KRW -788.6 million
- Net income (prior-year 3 months)
- KRW 341.2 million
- Net income (year to date)
- KRW -711.6 million
Commentary
AI commentary · Not investment advice
What happened
Jeil Bio Pharm's quarterly report covers the 3rd quarter of 2026 on a standalone basis.
In the company's terms
Sales for the 3 months were KRW 3.43 billion, down 23.1% from KRW 4.45 billion in the same period a year earlier. Cumulative sales this year were KRW 9.25 billion.
What changes for shareholders
Operating profit (profit from the core business) for the 3 months was a loss of KRW 328.3 million, a swing from a profit of KRW 325.5 million a year earlier. Cumulative operating profit this year was a loss of KRW 788.6 million.
Net income (final profit after taxes and all costs) for the 3 months was a loss of KRW 321.9 million, versus a profit of KRW 341.2 million a year earlier. Cumulative net income this year was a loss of KRW 711.6 million.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
J